Quanli L. Gao

No. 127 Dongming Road
Zhengzhou, 450008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.

Journal: JAMA oncology

Published: January 02, 2026

Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906).

Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906).

Journal: Frontiers in immunology

Published: December 18, 2025

Endogenous glucocorticoids and glucocorticoid receptor signaling: Dual regulators of PD-1/PD-L1 immunotherapy efficacy in the tumor microenvironment.

Endogenous glucocorticoids and glucocorticoid receptor signaling: Dual regulators of PD-1/PD-L1 immunotherapy efficacy in the tumor microenvironment.

Journal: Chinese medical journal

Published: May 25, 2025

The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis.

The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis.

Journal: Scientific reports

Published: February 27, 2025

Corrigendum to "CD69+ Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma" [Mol. Immunol. 172 (2024) 76-84].

Corrigendum to "CD69+ Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma" [Mol. Immunol. 172 (2024) 76-84].

Journal: Molecular immunology

Published: October 29, 2024

Role and regulatory mechanism of DLX5 in rhabdomyosarcoma tumorigenesis.

Role and regulatory mechanism of DLX5 in rhabdomyosarcoma tumorigenesis.

Journal: Biochimica et biophysica acta. Molecular cell research

Published: September 19, 2024

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial.

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial.

Journal: Journal for immunotherapy of cancer

Published: September 08, 2024

Impact of Tregs on tumor regression in locally advanced G/GEJ cancer patients undergoing neoadjuvant chemoimmunotherapy.

Impact of Tregs on tumor regression in locally advanced G/GEJ cancer patients undergoing neoadjuvant chemoimmunotherapy.

Journal: Scientific reports

Published: August 30, 2024

Utility of the neutrophil-to-lymphocyte ratio and the ratio of neutrophil-to-lymphocyte ratio after and before adverse events for differential diagnosis of immune-related adverse events and bacterial infections in cancer patients treated with PD-(L)1 inhibitors.

Utility of the neutrophil-to-lymphocyte ratio and the ratio of neutrophil-to-lymphocyte ratio after and before adverse events for differential diagnosis of immune-related adverse events and bacterial infections in cancer patients treated with PD-(L)1 inhibitors.

Journal: Journal of leukocyte biology

Published: August 12, 2024

Tongue squamous cell carcinoma treated by 5-aminolevulinic acid administrated through Microdrop method.

Tongue squamous cell carcinoma treated by 5-aminolevulinic acid administrated through Microdrop method.

Journal: Photodiagnosis and photodynamic therapy

Published: June 08, 2024

Transient-resting culture after activation enhances the generation of CD8+ stem cell-like memory T cells from peripheral blood mononuclear cells.

Transient-resting culture after activation enhances the generation of CD8+ stem cell-like memory T cells from peripheral blood mononuclear cells.

Journal: Translational oncology

Published: June 02, 2024

Pretreatment CD8 + PD-1 + to CD4 + PD-1 + ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors.

Pretreatment CD8 + PD-1 + to CD4 + PD-1 + ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors.

Journal: Melanoma research

Published: April 22, 2024

Showing 1-12 of 100

Last Updated: 09/26/2026